Document is current
Any future updates will be listed below
-
Authors
Morin, Cara E. https://orcid.org/0000-0003-1953-4486
McBee, Morgan P. https://orcid.org/0000-0002-7778-4152
Elbahlawan, Lama
Griffin, Lindsay M.
Maron, Gabriela M. https://orcid.org/0000-0001-5247-5399
Nguyen, HaiThuy N. https://orcid.org/0000-0002-4711-9928
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Snyder, Elizabeth J. https://orcid.org/0000-0002-1280-9697
Jeudy, Jean https://orcid.org/0000-0002-6028-459X
- License Information
-
More Information
Article History
Received: 8 December 2021
Revised: 1 March 2022
Accepted: 14 May 2022
First Online: 2 July 2022
Declarations
:
: Dr. A. Sharma has received a consultant fee from Spotlight Therapeutics and Medexus Inc. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. He is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287) and by Novartis (NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Dr. Sharma’s institution. These disclosures are not directly related to the content in this manuscript. Dr. Sharma also acknowledges support from the American Society of Hematology (ASH) Scholar Award. The other authors report no conflicts of interest.
